LONG BEACH, California, August 12, 2026, 05:30 EDT
- Rocket Lab stock gained 1.2% to $80.99 in premarket trade, according to preliminary pricing.
- Revenue for the second quarter totaled $234.1 million, and backlog rose to $2.36 billion.
- The midpoint for third-quarter guidance is roughly 8% higher than the previous analyst forecast.
Shares of Rocket Lab Corporation NASDAQ:RKLB rose ahead of Wednesday’s market open. Investors focused on the company’s record $2.36 billion order backlog and robust revenue expectations, offsetting concerns about a shortened 2026 launch window for Neutron. The regular session for the Nasdaq was closed while trading continued in premarket hours.
The stock completed a swift turnaround. After falling as much as 8.8% in early trading following Monday’s results, shares rebounded to end Tuesday nearly unchanged at $80.01, and added another 1.2% to reach $80.99 by 05:30 EDT. Premarket values are indicative and subject to change in light trading.
| Market measure | Latest | Investor comparison |
|---|---|---|
| Tuesday close | $80.01 | Fell 0.04% during the session |
| Wednesday premarket | $80.99 | Gained 1.22% in early trading; subject to revision |
| 52-week range | $37.57-$151.00 | Recent price trades 46% under the peak |
| Market value | $47.86 billion | Roughly 20 times the latest disclosed backlog |
From an investor’s perspective, order visibility is key. The backlog is currently around 2.5 times the annualized second-quarter revenue, providing coverage against uncertainty over launch dates. However, execution risk remains.
Revenue increased by 62% on the year to $234.1 million. Product sales surged to $181.3 million, representing 77% of total revenue. Service revenue totaled $52.7 million. Net loss decreased by 26% to $49.3 million.
| Second-quarter measure | Q2 2026 | Comparison |
|---|---|---|
| Revenue | $234.1 million | $144.5 million in the prior year period |
| Product revenue | $181.3 million | 77.5% of overall revenue |
| Service revenue | $52.7 million | 22.5% of overall revenue |
| GAAP net loss | $49.3 million | $66.4 million in the same quarter last year |
| GAAP loss per share | $0.08 | $0.13 in the prior-year quarter |
Rocket Lab surpassed its earlier forecasts. Guidance for the first quarter projected revenue between $225 million and $240 million, and the company delivered $234.1 million. Adjusted gross margin reached 41.5%, ahead of the 38% consensus estimate reported before the results came out.
The company forecast third-quarter revenue in the range of $250 million to $265 million. The midpoint, $257.5 million, represents a 10% increase from the second quarter and is around 8% above analysts’ earlier estimate of $238.5 million. This outlook was underpinned by more than $1 billion in new contracts awarded during the third quarter.
| Growth indicator | Latest value | Change or test |
|---|---|---|
| Backlog | $2.36 billion | Risen 137% from a year earlier |
| Backlog versus Q1 | +$160 million | Increased 7.3% from prior quarter |
| Q3 revenue guide | $250-$265 million | Midpoint stands 10% higher than Q2 |
| Guide versus prior consensus | +$19.0 million | Midpoint roughly 8% above previous view |
| Backlog coverage | 2.5 times | Compared with annualized Q2 revenue |
The timing of Neutron’s debut is still uncertain. Rocket Lab intends to move the medium-lift rocket to the launch pad during the fourth quarter. However, the likelihood of an inaugural launch within the year is decreasing. Chief Executive Peter Beck noted the “window for an end-of-year launch is narrowing.” Reuters
The postponement did not diminish demand. Rocket Lab secured a $266 million contract with the U.S. Space Force in July, providing for up to 18 suborbital launches. This deal represents the company’s biggest launch contract to date.
Wall Street sentiment is upbeat, but price targets are highly divergent. Thirteen analysts have Buy ratings on the stock, while four suggest Hold. No analyst currently rates it as a Sell. The mean target stands at $110.93, which is roughly 37% higher than the premarket indication. The lowest forecast, at $60, highlights the broad range of analyst opinions on Neutron launch timing.
| Analyst recommendation | Firm | Rating | Price target | Update |
|---|---|---|---|---|
| Top new target | KeyBanc | Buy | $135 | August 11 |
| Near the top of range | Stifel | Buy | $132 | August 11 |
| Typical consensus | Needham | Buy | $120 | August 11 |
| New cautious outlook | Piper Sandler | Hold | $83 | August 11 |
| Lowest set target | Wells Fargo | Hold | $60 | Earlier |
| Consensus overview | 17 analysts | 13 Buy, 4 Hold, 0 Sell | $110.93 average | Latest available |
The stock remains highly valued. With a market capitalization of $47.9 billion, it trades at roughly 20 times its backlog. This figure does not represent a price-to-sales ratio, as backlog is recognized gradually. The timing of contract execution, profitability, and possible cancellations are also key factors.
Risks: Neutron may be delayed past 2026, and third-quarter mix has potential to weigh on gross margin. Government contracts might also move between reporting periods. With a 2.60 beta and low premarket trading volume, price volatility could be heightened.
Investors are set to assess how backlog conversion compares with development expenditure. If Q3 results align with the mid-range of guidance, revenue growth would continue. The arrival of Neutron hardware at the pad would be even more significant. Each milestone is important.
Related articles: NASDAQ:RKLB
